A5093091933- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- RNA Interference and Gene Delivery
- CAR-T cell therapy research
- Virus-based gene therapy research
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2025
Vita-Salute San Raffaele University
2023-2025
The San Raffaele Telethon Institute for Gene Therapy
2023-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2023-2024
Liver metastases are associated with poor response to current pharmacological treatments, including immunotherapy. We describe a lentiviral vector (LV) platform selectively engineer liver macrophages, Kupffer cells and tumor-associated macrophages (TAMs), deliver type I interferon (IFNα) metastases. Gene-based IFNα delivery delays the growth of colorectal pancreatic ductal adenocarcinoma in mice. Response is TAM immune activation, enhanced MHC-II-restricted antigen presentation reduced...
Despite recent progress in cancer treatment, liver metastases persist as an unmet clinical need. Here, we show that arming and tumor-associated macrophages vivo to co-express tumor antigens (TAs), IFNα, IL-12 unleashes robust anti-tumor immune responses, leading the regression of metastases. Mechanistically, armed expand reactive CD8+ T cells, which acquire features progenitor exhausted cells kill independently CD4+ cell help. IFNα produced by reprogram antigen presenting rewire cellular...
Liver metastases (LMS) commonly arise from gastrointestinal tumors, such as colorectal cancer (CRC) and pancreatic (PDAC). The immunosuppressive environment of the liver favors cell seeding metastasis generation by impairing immune activation promoting escape. In agreement with this observation, most pharmacological interventions, including recent immunotherapies, prove ineffective in presence LMS. For example, immunotherapeutic treatments, which are successful against melanoma, show reduced...